Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
United Therapeutics Corp banner

United Therapeutics Corp
SWB:UTH

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
SWB:UTH
Watchlist
Price: 447.6 EUR -0.16% Market Closed
Market Cap: €12.6B
Write Note Create Alert Ask AI

Wall St Price Targets

UTH Price Forecast
Based on 15 analysts

+33% Upside
from €447.6 today

UTH Analyst Rating
No ratings yet

No rating

We don't have analyst ratings for UTH yet.

United Therapeutics Corp Competitors:
Price Targets

Revenue
Forecast

10% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
10% / Year
Past Growth
13% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 8 years is 13%.

What are analyst estimates?

Gross Profit
Forecast

10% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
10% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 6 years is 15%.

What are analyst estimates?

Operating Income
Forecast

10% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
10% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 8 years is 14%.

What are analyst estimates?

Pre-Tax Income
Forecast

11% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
11% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 11%. The projected CAGR for the next 3 years is 8%.

What are analyst estimates?

Net Income
Forecast

12% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
12% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 8 years is 11%.

What are analyst estimates?

Continue UTH Research

Summary
UTH intrinsic value, competitors valuation, and company profile.
DCF Valuation
UTH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
UTH stock valuation using valuation multiples.
Wall St Estimates
UTH price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
UTH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other United Therapeutics Corp listings:
NASDAQ • USD
UTHR
 F • EUR
UTH
 XMUN • EUR
UTH
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is UTH's stock price target?
Price Target
593.84 EUR

According to Wall Street analysts, the average 1-year price target for UTH is 593.84 EUR with a low forecast of 447.31 EUR and a high forecast of 654.65 EUR.

What is the Revenue forecast for United Therapeutics Corp?
Projected CAGR
13%

Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 8 years is 13%.

What is the Gross Profit forecast for United Therapeutics Corp?
Projected CAGR
15%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 10%. The projected CAGR for the next 6 years is 15%.

What is the Operating Income forecast for United Therapeutics Corp?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 8 years is 14%.

What is the Pre-Tax Income forecast for United Therapeutics Corp?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 11%. The projected CAGR for the next 3 years is 8%.

What is the Net Income forecast for United Therapeutics Corp?
Projected CAGR
11%

Over the last 13 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 8 years is 11%.

Back to Top
ALPHA SPREAD
Follow us
Join 358,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.